Sintilimab plus a bevacizumab biosimilar versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: updated results from the ORIENT-32 randomized phase 2–3 trial
求助中
20
由 123 发布于 2026/8/10 16:22:25
文献类型：期刊论文
补充材料：只需要正文
补充材料：只需要正文
其它数据库
应助信息
上传文件
等您来应助
9小时前
不是朋友交不起
846e196e949511f1999734735aa3bc31.pdf
已驳回
9小时前
Book学术机器人
2026/8/10 16:22:25
未找到该文献，机器人已退出，请等待人工下载
2026/8/10 16:22:25
Book学术AI机器人收到请求，开始寻找文献
2026/8/10 16:22:25
已向机器人发送请求
9小时前
123
发布求助
上一个求助:
其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary
下一个求助:
ElsevierEffects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study.
其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary
下一个求助:ElsevierEffects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study.
京公网安备 11010802042870号
